The famous Ozempic has been revolutionizing the treatment of type 2 diabetes for years and also has an important effect on obesity when it comes to helping patients lose weight by causing a greater satiety. However, the scientific community had long suspected that its effects went far beyond weight control and now, science has an idea that it may have an effect on alcohol.
New advances. A new study published earlier this month in The Lancet ha proven that these drugs are capable of significantly reducing the days of excessive alcohol consumption in patients who have an alcoholism problem.
Something that is a great milestone, since until now the evidence on the use of these drugs to treat addictions was based on small studies, but now a big change has been made by designing a trial with the maximum guarantees to find a clear relationship between taking Ozempic and the control of addiction.
How it was done. For 26 weeks, researchers followed 108 adult patients who had both obesity and an alcohol use disorder. From this sample, the group treated with semaglutide once a week experienced a 41% reduction in days of heavy drinking, compared to 26% in the placebo group not taking the treatment.
In addition, patients on medication consumed an average of 1,026 grams of alcohol per month, which is a significantly lower figure considering that the control group drank 1,550 grams of alcohol. And they both thought they were taking the same treatment, although that was not the case.
It’s not magic. To understand why this happens, we have to go to 2023, where a study showed that semaglutide, which is the active ingredient in Ozempic, binds directly to the nucleus accumbens of mice. By doing so, it suppresses the release of dopamine induced by alcohol consumption, suppressing the reward circuit that generates satisfaction when you drink a little alcohol and that is the effect that addicts seek. In this way, if alcohol does not generate that chemical “high”, the desire to consume it disappears.
The limitations. Despite the enthusiasm that this may generate for having a new treatment against alcoholism, which is an addiction that has great negative effects, we must put the brakes on a little. At a technical level, we must keep in mind that 108 people is still a relatively small group to extrapolate the results to the entire population.
Furthermore, all patients who participated in the study were obese and white, which limits the generalizability of the results to patients of normal weight or other ethnicities. And as if those were not enough limitations, it should be noted that the trial was funded by the drug manufacturers and does not have follow-up data beyond week 26.
Images | freepik freepic.diller on Magnific
GIPHY App Key not set. Please check settings